Current estimates indicate that approximately one-third of all disease-causing mutations are expected to disrupt splicing. Abnormal splicing often leads to disruption of the reading frame with introduction of a premature termination codon (PTC) that targets the mRNA for degradation in the cytoplasm by nonsense mediated decay (NMD). In addition to NMD there are RNA surveillance mechanisms that act in the nucleus while transcripts are still associated with the chromatin template. However, the significance of nuclear RNA quality control in the context of human genetic diseases is unknown. Here we used patientderived lymphoblastoid cell lines as disease models to address how biogenesis of mRNAs is affected by splice site mutations. We observed that most of the mutations analyzed introduce PTCs and trigger mRNA degradation in the cytoplasm. However, for some mutant transcripts, RNA levels associated with chromatin were found down-regulated. Quantification of nascent transcripts further revealed that a subset of genes containing splicing mutations (SM) have reduced transcriptional activity. Following treatment with the translation inhibitor cycloheximide the cytoplasmic levels of mutant RNAs increased, while the levels of chromatin-associated transcripts remained unaltered. These results suggest that transcription-coupled surveillance mechanisms operate independently from NMD to reduce cellular levels of abnormal RNAs caused by SM.
Introduction
Recent studies indicate that an unexpected high fraction of human diseases are caused by mutations that disrupt splicing. Approximately 15% of disease-causing mutations in the Human Gene Mutation Database (1) alter the consensus splice site sequences and another 22% are predicted to affect splicing enhancer or inhibitory motifs (2) . Thus, altogether approximately one-third of all disease-causing mutations are assumed to affect splicing. The phenotypic outcome of these mutations can be summarized in three distinct categories: (1) Constitutive exon skipping or intron retention; (2) altered inclusion/ exclusion ratio of alternative exons; and (3) activation of cryptic splice sites, resulting in inclusion/ exclusion of sequences in a spliced mRNA. Most often the final result is gene loss of function due to either synthesis of a non-functional protein or disruption of the reading frame that introduces a premature termination codon (PTC) and targets the mRNA for degradation by nonsense mediated decay (NMD) (3) .
Although NMD is a highly efficient post-transcriptional quality control mechanism that detects and destroys aberrant mRNAs containing PTCs (4), additional surveillance pathways ensure transcriptome fidelity. In particular, there is growing evidence indicating that cells can co-transcriptionally initiate the removal of abnormally processed pre-mRNAs as well as downregulate transcription when pre-mRNA processing repeatedly fails (5) . To date, several studies have characterized co-transcriptional RNA surveillance pathways in yeast and mammalian cells. In yeast, mutations in the splicing machinery did not result in steady-state accumulation of unspliced pre-mRNA unless the exosome was rendered defective (6) . These early experiments suggested that aberrantly processed transcripts are recognized and targeted for degradation by the exosome in the nucleus. A potential player in this process is the poly(A) binding protein Nab2p/Pab2p, which binds to the poly(A) tails of unspliced premRNAs and recruits the exosome for degradation (7, 8) . Studies in yeast further argue for a presumably distinct nuclear quality control mechanism that slows down or prevents release of aberrantly processed RNAs from the transcription site. Retention of transcripts at the transcription site occurs in cells with mutations in components of the 3′-end processing machinery and in factors required for mRNA export (reviewed in 9). Retention at the transcription site was also observed in mammalian cells for mutant β-globin pre-mRNAs that failed to be efficiently spliced or 3′-end processed (10) , and accumulation of mutant β-globin transcripts in association with chromatin was found to be exosome-dependent (11) . Co-transcriptional destruction of aberrantly processed RNAs by the exonuclease Xrn2 has also been recently reported in human cells (12) .
Whether co-transcriptional RNA quality control plays a physiological role in the context of human genetic diseases is unknown. To start addressing this issue, we used patient-derived lymphoblastoid cell lines to analyze the life cycle of RNAs produced from genes that contain disease-causing splicing mutations (SM). For a subset of the mutant genes, we found lower steady-state levels of RNAs associated with chromatin and reduced transcriptional activity. Treatment of cells with cycloheximide did not alter the levels of chromatin-associated mutant RNAs, suggesting a quality control mechanism independent from NMD.
Results
Epstein-Barr virus-immortalized lymphoblastoid cell lines were used as a model to study the impact of disease-causing SM on the biogenesis of mRNA. To obtain quantitative information on RNA levels, we used a biochemical fractionation approach that allows dynamic changes in transcription or nuclear RNA degradation to be distinguished from changes in cytoplasmic steadystate mRNA levels (Fig. 1A) . We optimized for lymphoblastoid cells a fractionation technique that was initially described by Wuarin and Schibler (13) and subsequently modified in the Proudfoot and Black laboratories (14, 15) . The protocol takes advantage of the fact that once RNA polymerase II (RNAPII) initiates transcription it forms a tight complex with the DNA template that resists treatment with urea and mild detergent. The extraction procedure does not dissociate histones from DNA and therefore the chromatin remains highly compacted and can be sedimented with associated nascent transcripts by low-speed centrifugation. Transcripts detected in the nucleoplasmic supernatant fraction are assumed to have been released from the DNA template. The efficiency of the fractionation protocol was assessed by western blotting (Fig. 1B) and RT-PCR (Fig. 1C) . For the western blotting (WB) assay antibodies against lamin A/C, β-actin, U2B″ and histone H3 proteins were used (Fig. 1B) . Actin was found predominantly in the cytoplasmic fraction, whereas U2 snRNP specific protein B″ (U2B″), lamin A/C and histone H3 were detected exclusively in nuclear fractions. The nucleoplasmic fraction should contain nuclear proteins that either do not associate with chromatin or are loosely attached to chromatin. The U2B″ is mostly detected in the nucleoplasmic fraction as previously reported for other components of the spliceosome (14) . Lamin and histone H3 are well-known chromatin-associated proteins and, accordingly, they are predominantly detected in the chromatin fraction. To characterize the RNA species present in each fraction, RT-PCR analysis was carried out with primers for total, unspliced and spliced Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA, as well as primers for Xist RNA (Fig. 1C) . The results clearly show that unspliced GAPDH premRNA is restricted to the nucleus and localizes predominantly in the chromatin fraction. Spliced mRNA is also detected in the chromatin fraction, consistent with the view that most splicing occurs co-transcriptionally (16) , but is most abundant in the cytoplasm. The distribution of total GAPDH RNA is similar to that of spliced mRNA, as expected considering that mature transcripts are transported and accumulate in the cytoplasm. A completely different distribution pattern is observed for Xist RNA, which is restricted to the nucleus and predominantly localized in the chromatin fraction consistent with its well-established physical interaction with the X-chromosome (17) .
Having validated the fractionation methodology, we next determined RNA levels in cell lines derived from a healthy donor and from patients affected by three distinct monogenic recessive disorders associated with SM: Barth syndrome (OMIM 302060), Deafness, autosomal recessive 49 (OMIM 610153) and Xeroderma Pigmentosum (OMIM 278720).
Barth syndrome is a X-linked recessive syndrome caused by mutations in the TAZ gene (MIM: 300394), which codes for an acyltransferase required for remodeling of cardiolipin in the inner mitochondrial membrane. TAZ loss of function results in an inborn error of lipid metabolism (18) (19) (20) . We analyzed two patient-derived cell lines, each containing a point mutation that affects splicing of the TAZ gene. The SM localize in intron 1, at the 5′ and 3′ splice sites (Table 1 and Fig. 2A) . It was previously shown that the 5′ splice site mutation activates two cryptic donor splice sites either upstream or downstream of the point mutation, and the 3′ splice site mutation can either activate a cryptic acceptor splice site within exon 2 or lead to exon 2 skipping (21) . Most 5′SM transcripts expressed in lymphoblastoid cells correspond to the longer splice product, which does not disrupt the open reading frame. The less abundant shorter splice product has the open reading frame disrupted (21) . The two splice products resulting from the 3′ splice site mutation are expressed at similar levels and only one has the open reading frame disrupted (21) . For comparison, we analyzed a cell line with a point mutation in exon 2 that introduces a PTC without affecting splicing frame (19) .
RNA levels were measured by quantitative real-time RT-PCR (qRT-PCR) using the primers indicated in Figure 2A . Figure 2B depicts the level of mutant transcripts in total cellular RNA as fold change relative to values detected using the same primer sets in cells from a healthy donor. The abundance of each PCR product was normalized to the level of GAPDH RNA detected in the same qRT-PCR run. The results show that the three mutant transcripts analyzed are significantly less abundant than wild-type (WT) TAZ RNA (Fig. 2B ), in agreement with the loss of function phenotype observed in patients. Next we determined the levels of mutant transcripts in the cytoplasm, nucleoplasm and chromatin, using equal amounts of RNA from each fraction. The cytoplasmic levels of the three mutant TAZ RNAs are significantly reduced relative to the WT (Fig. 2C) . However, distinct scenarios are observed in nuclear fractions ( Fig. 2D and E) . Mutant transcripts that contain a PTC but have normal splicing do not significantly differ from WT, suggesting that these RNAs are exclusively degraded in the cytoplasm ( Fig. 2D and E, PTC). In contrast, transcripts with the 5′ splice site mutation are significantly less abundant than WT transcripts in both nucleoplasm and chromatin fractions ( Fig. 2D and E, 5′SM). The level of transcripts with the 3′ splice site mutation is similar to WT in the nucleoplasm (Fig. 2D, 3′SM ), but higher in the chromatin (Fig. 2E, 3′SM ). This heterogeneity of results prompted us to analyze additional mutant transcripts associated with unrelated diseases.
Deafness, autosomal recessive 49 is a congenital profound sensorineural hearing loss of all frequencies, caused by dysfunction of a tricellulin protein coded by the MARVELD2 gene (MIM: 610572). Tricellulin is a tight-junction protein that contributes to the structure and function of tricellular contacts of neighboring cells. Loss of function of this protein may selectively affect the cellular permeability to ions or small molecules, resulting in a toxic microenvironment for cochlear hair cells and subsequently ear loss (22, 24) . We analyzed cell lines derived from three patients, each homozygous for a distinct splice site mutation in the MARVELD2 gene (Table 1 and Fig. 3A ). The splice site mutations localize in intron 3 at the 3′ splice site, and in intron 4 at the 5′ splice site. The 5′ splice site mutations activate cryptic donor sites in intron 4, and the 3′ splice site mutation activates a cryptic acceptor site within exon 4; all the mutations lead to the production of mRNAs containing PTCs due to shifts in the open reading frame (22) . For comparison, we analyzed a cell line homozygous a point mutation in exon 5 that introduces a PTC without affecting splicing (22) . RNA levels were measured by qRT-PCR using the primers indicated in Figure 3A . Similarly to the results obtained with TAZ transcripts, the total cellular levels of the four mutant MARVELD2 RNAs are significantly reduced compared with WT (Fig. 3B) . Analysis of RNA levels in sub-cellular fractions reveals that mutant transcripts are significantly less abundant in the cytoplasm (Fig. 3C ), in agreement with the finding that they all contain PTCs. In nuclear fractions the levels of mutant transcripts that contain a PTC but have normal splicing are similar to WT ( Fig. 3D and E, PTC), indicating that these RNAs are exclusively degraded in the cytoplasm. However, all transcripts with SM are significantly less abundant in the nucleoplasm (Fig. 3D ). In the chromatin fraction, significantly reduced levels are only detected for the 3′ splice site mutant (Fig. 3E, 3′SM) .
As a third model we analyzed cells from a patient with Xeroderma pigmentosum, an autossomic recessive condition characterized by increased sensitivity to ultraviolet irradiation and increased risk of skin cancer. It is caused by mutations in the XPC gene (MIM: 613208), which encodes a protein required for DNA repair (23, 25) . The cell line analyzed is homozygous for two distinct mutations at the 3′ splice site of intron 11 (Table 1 and Fig. 4A ). These mutations lead to skipping of exon 12, retention of intron 11 and activation of a 3′ cryptic splice site in exon 12, resulting in introduction of PTCs (23) . Quantitative real-time RT-PCR using the primers indicated in Figure 4A reveals a significant reduction in the total cellular levels of mutant XPC RNA compared with WT (Fig. 4B) . Analysis of sub-cellular fractions further shows that mutant transcripts are significantly less abundant in the cytoplasm, nucleoplasm and chromatin (Fig. 4C, D and E).
Altogether these results show that SM are consistently associated with reduced mRNA levels in the cytoplasm and, for a subset of mutations, down-regulation of expression is also detected in the nucleus. In contrast, mRNAs resulting from point mutations that introduce a PTC but do not interfere with splicing appear exclusively down-regulated in the cytoplasm. To determine whether lower steady-state RNA levels in the nucleus result from reduced transcription of genes containing SM, we measured newly transcribed RNA levels by metabolic labeling with the natural uridine derivative 4-thiouridine (4sU). This approach qRT-PCR using primer sets for exon 4 and exon 11. The amount of PCR product obtained from each fraction was normalized to the level of GAPDH RNA detected in the same fraction. In all graphs shown, data are expressed as fold change relative to the levels of WT transcripts. The histograms depict mean and standard deviation of three independent experiments. The asterisk denotes statistically significant differences (Student's t-test, *P < 0.05, **P < 0.01).
provides direct access to newly synthesized transcripts with minimal toxic effects (26) , although it may induce a nucleolar stress response (27) . Nascent RNA was labeled by adding 4sU to the cell culture medium for 10 min followed by isolation of total cellular RNA. Newly transcribed RNA species containing thiol-groups were then biotinylated, purified using streptavidin-coated beads and analyzed by qRT-PCR (Fig. 5A) . As RNAPII transcribes with elongation rates ranging between 0.5 and 4 kb/min (29), synthesis of new TAZ RNAs may take from 2.5 to 20 min, whereas MARVELD2 and XPC RNAs may require between 7 or 8 min to approximately 1 h. Thus, we expect that after incubation with 4sU for 10 min, most labeled RNAs are in the process of being synthesized and therefore should be confined to the chromatin fraction. The results shown in Figure 5B are in very good agreement with this prediction. To assess the extent to which transcription of the TAZ, MARVELD2 and XPC genes differs between lymphoblastoid cell lines derived from normal individuals, we analyzed a recently reported microarray dataset (28) . The results show that the transcription rate of these genes is similar across cells from three distinct individuals (Fig. 5C) . Next, we compared the levels of nascent transcripts produced by WT and mutant genes using primers to amplify both exonic and intronic regions of TAZ (Fig. 5D), MARVELD2 (Fig. 5E) and XPC (Fig. 5F ) transcripts. A significant down-regulation of nascent transcripts is observed for the TAZ 5′ splice site (Fig. 5D, 5′SM ) and MARVELD2 3′ splice site (Fig. 5E, 3′SM ) mutants, strongly suggesting that these genes are less efficiently transcribed. No evidence for reduced transcriptional activity of the XPC 3′ splice site mutant gene is observed, arguing that the lower steady-state RNA levels detected in the chromatin fraction likely reflect rapid nuclear degradation of these transcripts.
To determine the contribution of NMD to the observed downregulation of mutant RNAs in each sub-cellular fraction, cells were treated with cycloheximide (CHX), a drug that inhibits translation and hence indirectly blocks NMD (30) . After 3 h of treatment, cells were fractionated and changes in RNA levels analyzed by qRT-PCR. RNA levels in each treated fraction (CHX+) are expressed as fold change relative to the levels in the corresponding non-treated fraction (CHX-; Figs 6-8A). Alternatively, mutant RNA levels in each treated fraction (CHX+) are expressed as fold change relative to the levels of WT transcripts in the corresponding fraction from treated cells (Figs 6-8B ). Analysis qRT-PCR using primer sets for exon 2 and exon 4. The amount of PCR product obtained from each fraction was normalized to the level of GAPDH RNA detected in the same fraction. In all graphs shown, data are expressed as fold change relative to the levels of WT transcripts. The histograms depict mean and standard deviation of three independent experiments. The asterisk denotes statistically significant differences (Student's t-test, *P < 0.05, **P < 0.01).
of TAZ (Fig. 6), MARVELD2 (Fig. 7) and XPC (Fig. 8 ) mutant and WT transcripts shows that treatment with CHX consistently results in an increase in RNA levels in the cytoplasm. This increase is most obvious for mutant transcripts, as expected since their degradation by NMD is most probably impaired by CHX. An exception is the MARVELD2 PTC mutant, which gives rise to RNAs that are not affected by CHX, suggesting that they escape NMD. Accordingly, this particular mutant has been described to encode a truncated tricellulin protein (22) . The finding that CHX induces accumulation of WT transcripts is also in agreement with previous reports (31, 32 ).
An accumulation of both WT and mutant RNAs is further detected in the nucleoplasm of CHX treated cells. This observation argues that the lower steady-state levels of mutant transcripts observed in association with the nucleoplasm without a corresponding decrease in the chromatin fraction could be due to contamination of the nucleoplasmic fraction by mRNAs that have already been exported from the nucleus but remain associated with the cytoplasmic side of the nuclear envelope, as previously proposed (4). In contrast, CHX does not significantly alter the levels of WT and mutant RNAs associated with the chromatin fraction. However, the levels of TAZ 5′SM, MARVELD2 3′SM and XPC 3′SM RNAs persist reduced compared with WT in the chromatin fraction of CHX treated cells (Figs 6-8B) . Noteworthy, TAZ 5′SM and MARVELD2 3′SM RNAs, which are less efficiently transcribed ( Fig. 5D and E) , respond less to CHX treatment than other mutant forms of the same gene. The mild effect of CHX on cytoplasmic levels of TAZ 5′SM transcripts is in agreement with the finding that the majority of these RNAs are devoid of PTCs and therefore should not be degraded by NMD. Taken together, these observations suggest that some SM result in RNAs that are primarily degraded by NMD in the cytoplasm, while others can be targeted by transcription-coupled quality control mechanisms that operate independently from NMD.
Discussion
The results reported in this study suggest that splice site mutations in human cells trigger chromatin-associated RNA surveillance responses that contribute to down-regulate the In all graphs shown, data are expressed as fold change relative to the levels of WT transcripts. The histograms depict mean and standard deviation of three independent experiments. The asterisk denotes statistically significant differences (Student's t-test, **P < 0.01).
Human Molecular Genetics, 2015, Vol. 24, No. 10 | 2789 expression of abnormal mRNAs independently of NMD. We analyzed six cell lines derived from patients carrying SM and in three of them we found reduced mutant RNA levels associated with chromatin. In two of these lines, lower abundance of mutant chromatin-associated RNA correlated with reduced transcriptional activity. chromatin). RNA tagged with 4sU was purified from each fraction and analyzed by qRT-PCR as described in figures 2, 3 and 4. AU (arbitrary units). (C) Inter-individual differences of 4sU-tagged RNA. Nascent RNAs were isolated from lymphoblastoid cell lines derived from three unrelated healthy individuals (GM7029, GM10835 and GM12813) after incubation with 4sU for 2 h (analysis of GSE34204 dataset, (28) ). The amount of labeled TAZ, MARVELD2 and XPC RNA was normalized to the level of labeled GAPDH RNA detected in the same cell line. The histogram depicts mean and standard deviation of three biological replicates (independent cell cultures). AU (arbitrary units). (D-F) Quantification of nascent transcripts produced by WT and mutant genes. Cells were incubated with 4sU for 10 min. Total 4sU-tagged RNA was purified and analyzed by qRT-PCR using primers that recognize exonic (top) or intronic (bottom) regions. The amount of PCR product in each cell type was normalized to the level of GAPDH RNA detected in the same cell type. Data are expressed as fold change relative to the levels of WT transcripts. The histograms depict mean and standard deviation of three independent experiments. The asterisk denotes statistically significant differences (Student's t-test, *P < 0.05).
A link between SM and transcription was previously described (33, 34) . In the study by Damgaard et al., mutations in the promoter-proximal 5′ splice site were shown to severely decrease transcription by a mechanism that involved U1 snRNA recognition and assembly of the preinitiation complex (33). Here we observe a similar scenario for the TAZ 5′ splice site mutant. However, we also detected decreased transcription of the MARVELD2 3′SM gene, which contains a 3′ splice site mutation in the third intron. This observation raises the possibility that additional mechanisms are involved in coupling transcription to splicing efficiency. Indeed, inefficient splicing can cause stalling of spliceosomes on the transcripts, leading to recruitment of the RNAi machinery, heterochromatin formation and transcriptional silencing (35, 36) . Down-regulating the transcription of mutant genes appears 'economical', as it saves energy in producing and discarding aberrant RNAs. Yet, many transcripts produced from genes with SM escape this type of control.
Although transcription from the TAZ 3′SM and XPC 3′SM genes is similar to WT, RNA levels associated with chromatin differ significantly. The steady-state level of chromatin-associated TAZ 3′SM transcripts is higher than WT, whereas XPC 3′ SM transcripts are reduced compared with WT. The results obtained with TAZ 3′SM transcripts are reminiscent of our previous observations with β-globin splicing mutants (10, 11) , suggesting that abnormally processed RNAs persist associated with the chromatin template and consequently accumulate in this fraction. In contrast, the results obtained with XPC 3′SM suggest that these transcripts undergo a fast co-transcriptional decay most likely mediated by the exosome and/or Xrn2 (12) .
A main conclusion from this study is that disease-causing SM can have a variety of effects on mRNA biogenesis. For all diseaseassociated genes analyzed, a single splice site mutation leads to expression of multiple mRNA isoforms. Some of these isoforms may contain a PTC due to a frame shift caused by activation of a cryptic splice site or exon skipping, others may be recognized as abnormally spliced due to intron retention, while others may not be recognized as faulty (namely, if the reading frame is not disrupted). Thus, depending on the isoform expressed, the Figure 6 . Effect of cycloheximide on TAZ transcripts. Cells were either non-treated (CHX-) or treated with cycloheximide for 3 h (CHX+). The levels of WT and mutant transcripts in each sub-cellular fraction were analysed by qRT-PCR using the indicated primer sets. The amount of PCR product was always normalized to the level of GAPDH RNA. Data are expressed as fold change relative to the levels of non-treated cells (A) or as fold change relative to the levels of WT transcripts in treated cells (B). The histograms depict mean and standard deviation of three independent experiments. The asterisk denotes statistically significant differences (Student's t-test, *P < 0.05, **P < 0.01).
Human Molecular Genetics, 2015, Vol. 24, No. 10 | 2791 mutant RNAs may be differentially recognized by distinct surveillance mechanisms. We also found that TAZ, MARVELD2 and XPC genes are expressed at low levels in immortalized lymphoblastoid cells. Since the proteins encoded by these genes have tissue-specific functions, it remains to be established whether the patterns of mRNA biogenesis observed in lymphoblastoid cells are physiologically representative. Another limitation of working with immortalized lymphoblastoid cell lines is that these cells were resistant to RNA interference manipulations aimed at identifying the nucleases responsible for mutant RNA degradation in the nucleus. For future studies, induced pluripotent stem cells (iPSCs) derived from patients are likely to represent improved disease models. Differentiation of iPSCs into the specific cell types that require expression of the mutant genes for their normal function will provide a valuable system to address how cytoplasmic and nuclear quality control mechanisms operate to reduce expression of abnormal RNAs caused by SM.
In summary, our data supports the view that multiple layers of surveillance occur both in the nucleus and in the cytoplasm to minimize potentially toxic effects caused by faulty mRNAs. Although it is not yet possible to predict which SM will target RNAs for co-transcriptional surveillance, we expect this work will contribute to open new research venues addressing the impact of transcription-coupled non-NMD quality control pathways in the context of human genetic diseases. Ultimately, understanding how disease-causing SM are recognized by cellular quality control mechanisms may help in the rational design of more effective therapies for these disorders.
Materials and Methods

Cells and drug treatment
Lymphoblastoid cell lines immortalized by Epstein-Barr virus infection were obtained from the NIGMS Human Genetic Cell Figure 7 . Effect of cycloheximide on MARVELD2 transcripts. Cells were either non-treated (CHX-) or treated with cycloheximide for 3 h (CHX+). The levels of WT and mutant transcripts in each sub-cellular fraction were analysed by qRT-PCR using the indicated primer sets. The amount of PCR product was always normalized to the level of GAPDH RNA. Data are expressed as fold change relative to the levels of non-treated cells (A) or as fold change relative to the levels of WT transcripts in treated cells (B). The histograms depict mean and standard deviation of three independent experiments. The asterisk denotes statistically significant differences (Student's t-test, *P < 0.05, **P < 0.01).
Repository collections of the Coriell Institute for Medical Research, USA. Barth syndrome cell lines are GM22129; GM22165; and GM22150. Deafness, autosomal recessive 49 cell lines are GM20190; GM20193; GM20172; GM20189 and Xeroderma Pigmentosum cell line is GM04490. The healthy donor cell line is GM16113. The cell lines are described in detail in Table 1 . Cells were cultured in RPMI 1640 medium supplemented with 18% heat-inactivated serum, 2 m non-essential amino acid solution and 2 m L-Glutamin at 37°C in 5% CO 2 . All cell culture reagents were from Gibco, UK. Cells were treated with 50 µg/ml cycloheximide (C7698, Sigma, USA) for 3 h at 37°C.
Total RNA isolation and sub-cellular fractionation Nuclear and cytoplasmic RNA fractions were isolated as described (37) . Briefly, cells were incubated in RSB buffer (10 m Tris, pH 7.4, 10 m NaCl, 3 m MgCl 2 ) for swelling, centrifuged and resuspended in RSBG40 buffer (10 m Tris, pH 7.4, 10 m NaCl, 3 m MgCl 2 , 10% glycerol, 0.2% Nonidet P-40, 0.5 m dithiothreitol and 40 U/ml RNase) for lyses of the cell membrane. The fractionation of the nuclei into chromatin-associated and nucleoplasmic RNA was adapted from (13) (14) (15) . The nuclear pellet was gently resuspended in a prechilled glycerol buffer (20 m Figure 8 . Effect of cycloheximide on XPC transcripts. Cells were either non-treated (CHX-) or treated with cycloheximide for 3 h (CHX+). The levels of WT and mutant transcripts in each sub-cellular fraction were analysed by qRT-PCR using the indicated primer sets. The amount of PCR product was always normalized to the level of GAPDH RNA. Data are expressed as fold change relative to the levels of non-treated cells (A) or as fold change relative to the levels of WT transcripts in treated cells (B). The histograms depict mean and standard deviation of three independent experiments. The asterisk denotes statistically significant differences (Student's t-test, *P < 0.05, **P < 0.01).
Human Molecular Genetics, 2015, Vol. 24, No. 10 | 2793 Tris pH 7.9, 75 m NaCl, 0.5 m EDTA, 0.85 m DTT, 0.125 m PMSF and 50% glycerol) and an equal volume of cold nuclei lysis buffer (10 m HEPES pH7.6, 300 m NaCl, 0.2 m EDTA, 1 m DTT, 7.5 m MgCl 2 , 1 M Urea and 1% NP-40) was added. The tube was gently vortexed for 2 × 2 s and incubated for 10 min on ice. Chromatin was pelleted and incubated in 10 m Tris pH 7.5, 500 m NaCl, 10 m MgCl 2, 100 U/µl DNase I, 100 U/µl RNase OUT. RNA was extracted from each fraction and from the whole cell using PureZOL RNA isolation reagent (Bio-Rad, USA).
Immunoblotting
Immunoblotting of proteins extracted from each sub-cellular fraction was previously described (11) . The following primary antibodies were used: anti-lamin A/C (H-110, Santa Cruz Biotechnology, Inc); anti β-actin (Sigma); anti-U2B″ (clone 4G3, PROGEN Biotechnik GmbH); and anti-histone H3 (Abcam).
4sU Labeling
Nascent RNA was labeled with 4-thiouridine (Sigma, USA) as described (38) . Total RNA was extracted using PureZOL (BioRad, USA). Thiol-labeled RNA was biotinylated using EZ-Link Biotin-HPDP (Pierce, USA) and separated from untagged species using µMACS streptavidin-coated magnetic beads and columns (Miltenyi, Germany).
Quantitative real-time PCR
RNA was used as template for cDNA synthesis using random primers from the High Fidelity Kit (Roche) according to the manufacturer's instructions. PCR reactions were performed in the ViiA™ 7 Real-Time PCR System (Applied Biosystems, USA), using iTaq Universal SYBR Green Supermix (Bio-Rad, USA). Gene-specific primers are presented in Table 2 . Each sample was run in duplicate. The 2 −ΔCt method (39) was used to measure the relative changes in transcript levels.
Microarray data analysis
Data deposited in GEO database with the reference GSE34204 (28), were used for analysis. Microarrays were processed by using the AltAnalyze software version 2.0.8 (40) . Briefly, raw CEL data files from the deposited microarrays were normalized by the RMA algorithm. Probesets with detection above background (DABG) p-values above 0.5 or non-logarithmic expression below 1.0 were removed from the analysis. Gene expression levels were determined using only constitutive probesets, using the gene annotation present in AltAnalyze derived from Ensembl (41) and USCS (42) databases. 
